Heterogeneity (next 3 classes) 2 case studies –Age –Sexual activity –Others: Day care vs. not, Genetic heterog. Use data Understand behavior of complicated.

Slides:



Advertisements
Similar presentations
National Institute for Public Health and the Environment HIV, HCV, and HBV in injecting drug users in Europe Mirjam Kretzschmar Centre for Infectious Disease.
Advertisements

Feb 2011 Dr Guada Lopez Marti Pediatric Infectious Diseases Marshall University.
Derek A.T. Cummings University of Pittsburgh Graduate School of Public Health and Johns Hopkins Bloomberg School of Public Health Models of New Vaccines.
Issues in Genital Herpes
1 Workshop on the immunological basis of vaccine efficacy Vaccine and Infectious Disease Institute December 14, 2009 Ira M. Longini, Jr. Center for Statistical.
Epidemiologisten tartuntatautimallien perusteita Kari Auranen Rokoteosasto Kansanterveyslaitos Matematiikan ja tilastotieteen laitos Helsingin yliopisto.
Laboratory Training for Field Epidemiologists Sensitivity and specificity Predictive values positive and negative Interpretation of results Sep 2007.
End TB strategy target setting
Modelling HIV/AIDS in Southern Africa Centre for Actuarial Research (CARe) A Research Unit of the University of Cape Town.
The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.
Immune System Chapter 14.
What is a Vaccine? What Is A Vaccine? A vaccine is a substance that teaches the body’s immune system to recognize and protect against a disease caused.
Pneumonia Sapna Bamrah, MD CDC
Introduction to Risk Factors & Measures of Effect Meg McCarron, CDC.
Comparing Rubella Vaccination Strategies in China Linda Q. Gao North Central College Herbert Hethcote The University of Iowa May 18, 2004 DIMACS.
Modelling changes in HIV prevalence among women attending antenatal clinics in Uganda Brian Williams.
HIV Disease in Older Patients Donna M. Gallagher, ANP The International AIDS Society–USA DM Gallagher, ANP. Presented at IAS–USA/RWCA Clinical Conference,
Introduction to EPIDEMIOLOGY Daniel Cothran BIOL 422 – Microbiology 10/19/2009.
Jun,2002MTBI Cornell University Carlos Castillo-Chavez Department of Biological Statistics and Computational Biology Department of Theoretical and Applied.
Vaccination Poster. You will be creating and presenting a poster: Think about who your poster’s target audience might be… (ex. Parents, teenagers, pregnant.
Varicella Zoster Virus Herpesvirus (DNA) Primary infection results in varicella (chickenpox) Recurrent infection results in herpes zoster (shingles) Short.
How does mass immunisation affect disease incidence? Niels G Becker (with help from Peter Caley ) National Centre for Epidemiology and Population Health.
VACCINE Group V Eka Putri Dewi ( ) Ferlany Hardiyanti ( ) Nanda Yuli Rahmawati ( )
Measles Antibody Levels in U.S. Immune Globulin Products
Infectious Disease Epidemiology Sharyn Orton, Ph.D. American Red Cross, Rockville, MD Suggested reading: Modern Infectious Disease Epidemiology (1994)
21 August 2015 Samreen Ijaz Virus Reference Department Health Protection Agency Indigenous HEV infection in the UK: a hazard for blood donation?
Dr. Paramita Sengupta Department Of Community Medicine Christian Medical College Ludhiana Co-authors: Ragini Mann, Rohit Theodore, A I Benjamin Risk factors.
Guidance on Provider-initiated Voluntary Medical Examination, Testing and Counselling for Infectious Diseases in Injecting Drug Users Hans Blystad 1 and.
Lecture 3: Measuring the Occurrence of Disease
Perceived HIV risks, types of sexually transmitted diseases, and discordant infection status among low-tier female sex workers in China (Roundtable Presentation)
1 Universal Immunization Against Rare Diseases  How much is a child’s life worth?  The individual vs society.
Infectious disease, heterogeneous populations and public healthcare: the role of simple models SIAM CSE 2009 K.A. Jane White Centre for Mathematical Biology.
Summary of measures of population Health Farid Najafi MD PhD School of Population Health Kermanshah University of Medical Sciences.
Assessing the Response to Hepatitis B Immunizations in HIV-Positive Adults: Results from the 550 Clinic cohort study Camila Calderon 1, Anupama Raghuram.
Surveillance Plan for Bison Yellowstone National Park.
SIR Epidemic Models CS 390/590 Fall 2009
ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES XVIII International AIDS Conference, July , Vienna Austria Recent Trends in estimated HIV-1.
Aim: How do vaccinations protect us against disease ? Immunity is the ability of an organism to resist disease by identifying and destroying foreign substances.
Full papers:Nishiura H, Schwehm M, Eichner M. Epidemiology 2006; 17(5): Nishiura H, Eichner M. Infection 2006; 34: in press. Learning about long-term.
Decreasing Incidence of Pertussis in Massachusetts Following the Introduction of Tdap Noelle Cocoros, Nancy Harrington, Rosa Hernandez, Jennifer Myers,
Unit 12-13: Infectious Disease Epidemiology. Unit Learning Objectives: 1.Understand primary definitions used in infectious disease epidemiology.
Modelling infectious diseases Jean-François Boivin 25 October
Communicable Disease Disease passed from one person to another.
Epidemiology With Respect to the Dynamics of Infectious Diseases Huaizhi Chen.
BASICS OF EPIDEMIC MODELLING Kari Auranen Department of Vaccines National Public Health Institute (KTL), Finland Division of Biometry, Dpt. of Mathematics.
New vaccines mean new strategies: A theoretical exploration of the impact of HPV/HSV vaccines. Geoff Garnett Department of Infectious Disease Epidemiology,
Causation ? Tim Wiemken, PhD MPH CIC Assistant Professor Division of Infectious Diseases University of Louisville, Kentucky.
Infectious disease Definition
Disease ecology – SIR models ECOL 8310, 11/17/2015.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The threshold for an ART secondary prevention effect on HIV.
SIR Epidemic and Vaccination
Biological methods for assessing vaccination history: a role for serosurveillance in household surveys?
Annual Epidemiological Spotlight on HIV in London: 2014 data Field Epidemiology Services PHE Publications gateway number
Definition of disease A disease is an abnormal condition of an organism that impairs bodily functions, associated with specific symptoms and signs. It.
Dr.Noura Abouammoh Dr. Afnan Younis.  Define and calculate measure of frequency of disease (Prevalence, Incidence, Attack rate)  Be able to decide when.
Vaccination game. 32 Vaccinated 32 Susceptible Vaccination game.
Isolated Hepatitis B Core Antibody
III. Measures of Morbidity: Morbid means disease. Morbidity is an important part of community health. It gives an idea about disease status in that community.
NUR 431.  A discipline that provides structure for systematically studying health, disease, and conditions related to health status ◦ Distribution of.
Diagnosis of pulmonary tuberculosis
Comparing Australia with Developing Countries Morbidity, life expectancy, infant mortality, adult literacy and immunisation rates can be used to compare.
Active immunity and vaccination What is immunisation? The process by which a person develops immunity to a disease causing organism. i.e. the blood contains.
Herpes Simplex Virus Type 2 infection among U.S. military service members: Public Health Implications and Opportunities for HIV Prevention Christian T.
Rubella Surveillance and Control in Low-Resource Settings: Limitations, Biases, and Potential for Strengthening Amy Winter, PhD Candidate, Princeton University.
 Direct  Indirect  Direct: -Microscopy -Culture -Antigen -Nucleic acid  Indirect: -Specific antibody (Serology)
Depart. of Pulmonology 백승숙. More than 80% of cases of tuberculosis in the United States –The result of reactivated latent infection –Nearly all these.
IMMUNIZATION د. رائد كريم العكيلي
Modelling infectious diseases
Anatomy of an Epidemic.
Four indirect measures of TB incidence
Presentation transcript:

Heterogeneity (next 3 classes) 2 case studies –Age –Sexual activity –Others: Day care vs. not, Genetic heterog. Use data Understand behavior of complicated models

Age-Structured Serological Data (next 2 classes) Biological Basis Modeling context (multicompartment ODEs, PDEs) Estimate Age-Specific FOI Problems with interpretation Other interpretations Mixing Matrix (WAIFW) Elimination Threshold

Biology: Humoral Immune Response

Humoral immunity Protection from subsequent infection Standing antibody levels Long-lived antibody-secreting cells Ability to mount anamnestic (memory, 2 o ) response Record of history of infection Presence of antibody

Serological testing Assays: –ELISA: Count antibodies (usually IgG) –Functional assays: biological function Arbitrary cutoff for positivity must be specified: Continuous measurement [Ab] with cutoff SHOW Figs 1 and 2

Seroprevalence: involves making cutoffs in continuous data Rotavirus in Sao Paolo: MJ Cox et al Epidemiol Infect IgG IgMIgA

Same: RSV in Sao Paolo MJ Cox et al J Med Virol

Cellular immunity Important for protection (long-term immunity) vs. viruses, intracellular bacteria Less frequently assayed for history of infection Exception: TB skin test (tuberculin, PPD) –DTH: CD4+ T-cell mediated monocyte response –Ambiguous indicator of history of infection, protection

Antibody decline with age Significance for immunity to reinfection? Significance for record of infection? 3 weeks 70 years time ln [IgG] infection

Ideal Serological Marker of Infection permanent highly reproducible sensitive (everyone who has had the infection is positive on the test) specific (only people who have had the infection are positive on the test) biologically relevant (i.e., history of infection = immunity = assay positivity) -- DEPENDS ON BIOLOGY

Often ideals are approximately met, but problems include: waning immunity with age differences among individuals in their immune responses background ("natural" false positives, false positives induced by infection with related agents) ignorance of appropriate cutoffs (both for "record keeping" and for functional immunity)

Poor resolution at older ages for highly transmissible diseases MJ Cox et al J Med Virol FT Cutts et al J Med Virol

Hepatitis A in NL Termorshuizen et al Epidemiol Infect

And more.... Measles: US Measles: India, NigeriaMumps: E/W, NLPolio: US Malaria: NigeriaHBV: Senegal Rubella: GambiaRubella: E/W Abbreviation: E/W England & WalesAnderson & May Nature 1985

Uses of Age-SP Data Infer characteristics of transmission process –age-specific rates of infection –predictors of infection at various ages –changes in transmission over time Estimate age-specific: –force of infection ( ): (time-to-event analysis, same as survival analysis in other contexts) –incidence –transmission coefficients given a mixing matrix structure

From: OL Chason, DPH Thesis, HSPH, Diphtheria Immunity in Rural Alabama: A survey of social conditions, environment, and Schick Test Results

End of Biology Back to Models

Why to use an age-specific model? 1. To capture more accurately the dynamics of the population –Especially important when infectiousness is long relative to the lifespan (HSV, HIV) –Because death is then a likely end to infection, so modeling it correctly is important

Exponential stay in each compartment without age structure Non age-structured model S1S1 I1I1 R1R1 SS II RR No age component. Stay in any compartment has an exponential distribution Bad approximation for lifespan in developed countries

Why to use an age-specific model? 2. To keep track of when people get infected: important when –Different ages contribute to transmission differently –Age at infection matters to impact Cost Severity (chickenpox, rubella, flu) –Vaccines are introduced at ages other than near-birth

Idealized Population for Analyzing Age-Specific Data Everyone lives exactly L years and then dies Population is in demographic equilibrium: –N(0) born each year in our unit area –N(0) in each year’s age cohort in unit area Total population density is LN(0)

Multi Age-Group Model: compartments S1S1 S2S2 S3S I1I1 I2I2 I3I3 R1R1 R2R2 R3R (1/30)S 2 (1/15)S 1 (1/55)S 3

More compartments better approximate the ideal Ideal

PDE Model: Limiting Case ( ∞ age classes)

Using Age-Stratified Seroprevalence Data

Seropositives Incident infections Infectious cases (sources) CausalityInference Immunity

Calculations Seronegatives reduced by force of infection Incidence = force of infection * prop. Susceptible Prevalence ~ incidence * duration Note: lower case letters = proportions; capitals = densities)

Formal analysis of AS Data Start with AS profile Calculate Age-specific Force of Infection (a) Calculate Age-Specific Prevalence Y(a) Calculate Mixing Matrix Coefficients  ij given a structure

Calculating Force of Infection, Incidence and Prevalence from Serologic Data

Diphtheria Immunity in Rural Alabama, (whites) AgeS+S- IncPrev E E E E E E E E E E P S+ I

Diphtheria Immunity in Rural Alabama, (whites) P S+ I For age classes wider than 1 yr

Caveats

Data Available What we usually have: Cross-sectional age-seroprevalence What we usually want: Longitudinal (cohort) age-seroprevalence ?? WHEN ARE THESE THE SAME?

Looking at Cross-Sectional AS Data

HTLV-1

Other examples (EXCEL) STD that has been present for a long time New STD New zoonosis (e.g. tick-borne disease) Recently eradicated disease Disease transmitted primarily in childhood with fast waning of immunity

Genetic Heterogeneity in Susceptibility: Can Masquerade as Age-Heterogeneity Younger age classes: mix of genetically S & genetically R individuals, relatively high incidence Older age classes: S individuals will have been infected already: incidence will be rate relevant to R individuals Frailty model